Results 201-220 of 1,499 for drugs speaker:Stephen Donnelly
- Written Answers — Department of Health: Medicinal Products (22 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the Community Drug Schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013. Reimbursement is for licensed indications which have been granted market authorisation by the European Medicines Agency (EMA) or the Health...
- Written Answers — Department of Health: Medicinal Products (21 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drugs schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. Reimbursement for medicines under the community drugs schemes is for licensed indications which have been granted market authorisation by the European Medicines...
- Written Answers — Department of Health: Departmental Data (21 Jun 2023)
Stephen Donnelly: ...must be reviewed every third year after 2020. My Department is currently carrying out a review. Data in respect of the number of items dispensed by community pharmacists under the community drug schemes is available on the Primary Care Reimbursement Service (PCRS) website at the following link: www.sspcrs.ie/portal/annual-reporting/report/pharmacy This data includes the year 2022 and is...
- Written Answers — Department of Health: Pharmacy Services (20 Jun 2023)
Stephen Donnelly: ...to Community Pharmacy Contractors) Regulations 2019 – S.I. 639 of 2019 – which came into effect from 1 January 2020. Since then, the overall spend on fees paid to community pharmacists under the community drug schemes has continued to rise year-on-year. The Primary Care Reimbursement Service (PCRS) online system shows fees paid to pharmacies under the community drug schemes...
- Written Answers — Department of Health: Health Service Executive (20 Jun 2023)
Stephen Donnelly: ...for the advancement of the discipline of pharmacoeconomics through practice, research and education. The NCPE is an independent Health Technology Assessment (HTA) Agency responsible for evaluating drug treatments for use in the Irish healthcare setting. The NCPE conducts the HTA of drugs for the health service in Ireland in collaboration with the Health Service Executive's Corporate...
- Written Answers — Department of Health: Medicinal Products (20 Jun 2023)
Stephen Donnelly: The Drug Payment Scheme (DPS) provides for the refund of the amount by which expenditure on approved prescribed medicines or medical and surgical appliances exceeds a named threshold in any calendar month. The DPS is not means tested and is available to anyone ordinarily resident in Ireland. The DPS threshold was reduced twice in 2022: From €114 to €100 per month on 1 January...
- Written Answers — Department of Health: Medicinal Products (20 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drugs schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds, on the advice of the National Centre for...
- Written Answers — Department of Health: Health Services Staff (20 Jun 2023)
Stephen Donnelly: ...for the advancement of the discipline of pharmacoeconomics through practice, research and education. The NCPE is an independent Health Technology Assessment (HTA) Agency responsible for evaluating drug treatments for use in the Irish healthcare setting. The NCPE conducts the HTA of drugs for the health service in Ireland in collaboration with the Health Service Executive's Corporate...
- Written Answers — Department of Health: Medicinal Products (20 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drugs schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds, on the advice of the National Centre for...
- Written Answers — Department of Health: Medicinal Products (20 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drugs schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds, on the advice of the National Centre for...
- Written Answers — Department of Health: Health Services (15 Jun 2023)
Stephen Donnelly: ...in the country, i.e. full eligibility (medical card holders) and limited eligibility (all others). Adults with full eligibility can access a range of services including GP services, prescribed drugs and medicines, public in-patient hospital services, including consultants’ services, out-patient public hospital services including consultants’ services, dental, ophthalmic and...
- Written Answers — Department of Health: Pharmacy Services (15 Jun 2023)
Stephen Donnelly: ...to Community Pharmacy Contractors) Regulations 2019 – S.I. 639 of 2019 – which came into effect from 1 January 2020. Since then, the overall spend on fees paid to community pharmacists under the community drug schemes has continued to rise year-on-year. The Primary Care Reimbursement Service (PCRS) online system shows fees paid to pharmacies under the community drug schemes...
- Written Answers — Department of Health: Medicinal Products (15 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the Community Drug Schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013. Reimbursement is for licensed indications which have been granted market authorisation by the European Medicines Agency (EMA) or the Health...
- Written Answers — Department of Health: Medicinal Products (14 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the Community Drug Schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013. Reimbursement is for licenced indications which have been granted market authorisation by the European Medicines Agency (EMA) or the Health...
- Written Answers — Department of Health: State Bodies (13 Jun 2023)
Stephen Donnelly: ...for the advancement of the discipline of pharmacoeconomics through practice, research and education. The NCPE is an independent Health Technology Assessment (HTA) Agency responsible for evaluating drug treatments for use in the Irish healthcare setting. The NCPE conducts the HTA of drugs for the health service in Ireland in collaboration with the Health Service Executive's Corporate...
- Written Answers — Department of Health: Medicinal Products (13 Jun 2023)
Stephen Donnelly: ...; diabetes mellitus; parkinsonism; epilepsy; phenylketonuria; haemophilia; spina bifida; hydrocephalus; and conditions arising from the use of Thalidomide. Under the LTI Scheme, patients receive drugs, medicines, and medical and surgical appliances directly related to the treatment of their illness, free of charge. Statutory Instrument No. 277 of 1971 put the following limitation on the...
- Written Answers — Department of Health: Health Services (13 Jun 2023)
Stephen Donnelly: ...diabetes mellitus; parkinsonism; epilepsy; phenylketonuria; haemophilia; spina bifida; hydrocephalus; and conditions arising from the use of Thalidomide. Under the LTI Scheme, patients receive drugs, medicines, and medical and surgical appliances directly related to the treatment of their illness, free of charge. While there are no current plans to extend the list of illnesses...
- Written Answers — Department of Health: Medicinal Products (13 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. In October 2022, the HSE approved the drug Sunosi® (solriamfetol) for reimbursement under High Tech Arrangements subject to managed access for adult patients...
- Written Answers — Department of Health: Medicinal Products (13 Jun 2023)
Stephen Donnelly: The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement of medicines under the Community Drug Schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013. Reimbursement is for licensed indications which have been granted market authorisation by the European Medicines Agency (EMA) or the Health...
- Written Answers — Department of Health: Medicinal Products (13 Jun 2023)
Stephen Donnelly: Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.